VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
TRDA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
TRDAEntrada Therapeutics, Inc.
$5.03$195M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksTRDACash Flow

Entrada Therapeutics, Inc. (TRDA) Cash Flow Statement

7Y historyFree accessUpdated daily

Nine of ten quarters produced negative free cash flow totaling roughly $252M, with a -39.8% FCF margin in 2026Q2 and a cumulative $87M gap between $160.6M of net losses and $247.5M of operating cash outflow suggesting cash burn is running ahead of reported earnings.

Income StatementBalance SheetCash FlowRatios

TRDA Cash Flow Statement

Annual statement

TRDA Cash Flow Statement

Entrada Therapeutics, Inc. (TRDA) cash flow statement — 7-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Cash from Operations-136.32M-128.51M-41.56M139.8M-93.79M-50.86M-25.57M-10.8M
Operating CF Margin %--505.53%-19.72%108.36%----
Operating CF Growth %-26.09%-209.24%-129.73%249.07%-84.39%-98.91%-136.74%-
Net Income-161.39M-143.75M65.63M-6.68M-94.62M-51.16M-26.52M-5.1M
Depreciation & Amortization-469K4.1M3.77M2.84M1.9M1.12M326K104K
Stock-Based Compensation19.03M19.61M17.91M13.11M9.89M2.53M325K294K
Deferred Taxes00000000
Other Non-Cash Items1.78M-3.67M-10.02M-5.78M151K74K20K-6.27M
Working Capital Changes4.72M-4.8M-118.85M136.31M-11.11M-3.42M282K174K
Change in Receivables19K2.5M2.2M00000
Change in Inventory00000000
Change in Payables1.7M-1.8M991K-2.81M5.29M-715K631K367K
Cash from Investing153.98M116.81M-27.8M-138.4M-148.65M-4.58M-2.32M-630K
Capital Expenditures-9K-1.04M-3.16M-5.61M-2.89M-4.58M-2.32M-630K
CapEx % of Revenue0.23%4.09%1.5%4.35%----
Acquisitions00000000
Investments--------
Other Investing00000000
Cash from Financing642K887K102.96M21.04M479K307.46M50.09M38K
Debt Issued (Net)00000000
Equity Issued (Net)642K887K99.61M19.41M479K306.52M49.84M38K
Dividends Paid00000000
Share Repurchases00000000
Other Financing003.36M1.63M0939K247K0
Net Change in Cash18.29M-10.82M33.61M22.45M-245.91M252.02M22.2M16.84M
Free Cash Flow-136.33M-129.55M-44.72M134.19M-96.67M-55.44M-27.89M-11.43M
FCF Margin %-3428.06%-509.63%-21.21%104.01%----
FCF Growth %-5.04%-189.73%-133.32%238.81%-74.37%-98.8%-143.97%-
FCF per Share-3.22-3.13-1.154.06-3.09-1.78-0.89-10.91
FCF Conversion (FCF/Net Income)0.84x0.89x-0.63x-20.91x0.99x0.99x0.96x2.32x
Interest Paid00000000
Taxes Paid004.62M14.72M0000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Cash burn outpacing reported earnings

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Earnings and Cash Flow Diverge

Entrada's operating cash flow diverged sharply from reported earnings in 2024Q4, when a $1.1M net income coincided with a $31.6M cash outflow, an OCF/NI ratio of -27.94, according to the company's cash flow statements, underscoring that reported profitability has never translated into cash generation.

The OCF/NI ratio has swung from 2.22 in 2025Q1, where a $17.3M net loss met a $38.5M operating outflow, to 0.83 in 2026Q2, so the relationship between earnings and cash has never stabilized enough to treat either measure as a reliable anchor. Because cumulative operating cash outflow has run well ahead of cumulative reported losses, the income statement appears to be a poor proxy for the actual cash economics of the business.

Burn Persists Despite Revenue Collapse

Across the ten quarters presented, Entrada's free cash flow was negative in nine periods totaling roughly $252M of outflow, with the latest quarter showing a -39.8% FCF margin on an immaterial top line, as disclosed in its quarterly cash flow filings.

The burn has held in a $28M to $42M per quarter band since 2024Q3 even as revenue collapsed from $94.7M to under $1M, implying the outflow is overwhelmingly fixed R&D and SG&A spend rather than variable cost tied to commercial activity. With revenue now negligible, the FCF margin ratio has lost analytical value; the meaningful signal is the absolute quarterly burn and whether it is compressing, which it shows no clear sign of doing.

Working Capital Drives OCF Volatility

Working capital consumed $51.6M in 2024Q1 and $35.9M in 2024Q4 before swinging to a $10.2M source in 2025Q3, a reversal pattern that has materially shaped reported operating cash flow, per Entrada's consolidated statements of cash flows.

The magnitude of these swings often exceeds the underlying operating loss in the same quarter, suggesting working capital timing rather than earnings performance is the dominant driver of quarter-to-quarter OCF variation. For a business whose revenue is now immaterial, such large and directionally inconsistent working capital movements warrant further investigation into which balance sheet accounts are generating them, since they obscure the true operating burn.

Cumulative Cash Gap Exceeds Losses

Over the ten quarters presented, Entrada accumulated $160.6M of net losses against $247.5M of operating cash outflow, a cumulative gap of about $87M in which cash consumption has run materially ahead of reported earnings, based on Entrada's reported figures.

Excluding the two profitable periods of 2024Q2 and 2024Q4, every quarter shows both negative earnings and negative operating cash flow, with no visible trend toward convergence between the two lines. This persistent shortfall suggests that accruals, working capital movements and non-operating items may have systematically flattered cumulative reported performance relative to realized cash, which investors should weigh before relying on net income as a value measure.

Non-Cash Cushions Mask True Cost

Stock-based compensation added back to cash flow reached $9.9M in 2026Q2 versus $3.7M in 2024Q1, totaling roughly $52M across the period, while depreciation exceeded capital expenditure in most quarters, meaning reported operating outflows benefit from non-cash cushions.

That $52M of SBC never appears as an operating cash outflow, yet represents real dilution to continuing shareholders, so the reported OCF line simultaneously understates the economic cost of compensation and overstates the cash burden borne by owners. Depreciation running ahead of capex further indicates the existing asset base is being consumed rather than renewed, an effect entirely invisible in the headline OCF figure and one that may not be sustainable indefinitely.

Minimal Reinvestment Amid Heavy Operating Burn

Entrada's capital expenditure remained at or below $1.1M in every quarter of the period, dwarfed by quarterly depreciation running near $0.8M to $1.6M in most periods, as reported in its cash flow statements, signaling a business that is not reinvesting in productive assets.

Capex of this scale against quarterly operating losses near $40M means capital discipline is effectively irrelevant to the cash trajectory, which is set almost entirely by operating expense decisions rather than investment choices. The absence of meaningful reinvestment also implies there is little new asset base to generate future depreciation shelter, and investors should not expect capex to become a material cash user absent a strategic shift.

TRDA — Frequently Asked Questions

Quick answers to the most common questions about buying TRDA stock.

How much cash does Entrada Therapeutics, Inc. (TRDA) generate from operations?

Entrada Therapeutics, Inc. (TRDA) generated $-128.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Entrada Therapeutics, Inc.'s free cash flow?

Entrada Therapeutics, Inc. (TRDA) reported negative free cash flow of $129.6M in 2025, indicating capital requirements exceeded cash from operations.

What is Entrada Therapeutics, Inc.'s capital expenditure (CapEx)?

Entrada Therapeutics, Inc. (TRDA) spent $1.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.